{"id":"https://openalex.org/W4245665166","doi":"https://doi.org/10.1158/1538-7445.am2019-3880","title":"Abstract 3880: In vivo activities of TP-2846: a novel tetracycline antileukemia agent","display_name":"Abstract 3880: In vivo activities of TP-2846: a novel tetracycline antileukemia agent","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W4245665166","doi":"https://doi.org/10.1158/1538-7445.am2019-3880"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-3880","doi":"https://doi.org/10.1158/1538-7445.am2019-3880","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-3880","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055334054","display_name":"Xiao-Yi Xiao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151614","display_name":"Tetraphase Pharmaceuticals (United States)","ror":"https://ror.org/048830f73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiao-Yi Xiao","raw_affiliation_strings":["1Tetraphase Pharmaceuticals, Watertown, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Tetraphase Pharmaceuticals, Watertown, MA;","institution_ids":["https://openalex.org/I4210151614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049125764","display_name":"Cuixiang Sun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151614","display_name":"Tetraphase Pharmaceuticals (United States)","ror":"https://ror.org/048830f73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cuixiang Sun","raw_affiliation_strings":["1Tetraphase Pharmaceuticals, Watertown, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Tetraphase Pharmaceuticals, Watertown, MA;","institution_ids":["https://openalex.org/I4210151614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100327155","display_name":"Jian Zhou","orcid":"https://orcid.org/0000-0001-6032-1007","observed_orcids":["https://orcid.org/0000-0001-6032-1007"]},"institutions":[{"id":"https://openalex.org/I4210151614","display_name":"Tetraphase Pharmaceuticals (United States)","ror":"https://ror.org/048830f73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jian Zhou","raw_affiliation_strings":["1Tetraphase Pharmaceuticals, Watertown, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Tetraphase Pharmaceuticals, Watertown, MA;","institution_ids":["https://openalex.org/I4210151614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036758613","display_name":"Noriaki Tatsuta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151614","display_name":"Tetraphase Pharmaceuticals (United States)","ror":"https://ror.org/048830f73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Noriaki Tatsuta","raw_affiliation_strings":["1Tetraphase Pharmaceuticals, Watertown, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Tetraphase Pharmaceuticals, Watertown, MA;","institution_ids":["https://openalex.org/I4210151614"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Joseph Newman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151614","display_name":"Tetraphase Pharmaceuticals (United States)","ror":"https://ror.org/048830f73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Newman","raw_affiliation_strings":["1Tetraphase Pharmaceuticals, Watertown, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Tetraphase Pharmaceuticals, Watertown, MA;","institution_ids":["https://openalex.org/I4210151614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051833274","display_name":"Douglas B. White","orcid":"https://orcid.org/0000-0003-2269-4173","observed_orcids":["https://orcid.org/0000-0003-2269-4173"]},"institutions":[{"id":"https://openalex.org/I4210118680","display_name":"Cambridge Intellectual Property (United Kingdom)","ror":"https://ror.org/02pqvpt18","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210118680"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Douglas White","raw_affiliation_strings":["2Fractal Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fractal Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210118680"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084402708","display_name":"Barbara Hibner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118680","display_name":"Cambridge Intellectual Property (United Kingdom)","ror":"https://ror.org/02pqvpt18","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210118680"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Barbara Hibner","raw_affiliation_strings":["2Fractal Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fractal Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210118680"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003610011","display_name":"Arijit Chakravarty","orcid":"https://orcid.org/0000-0003-1338-5432","observed_orcids":["https://orcid.org/0000-0003-1338-5432"]},"institutions":[{"id":"https://openalex.org/I4210118680","display_name":"Cambridge Intellectual Property (United Kingdom)","ror":"https://ror.org/02pqvpt18","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210118680"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Arijit Chakravarty","raw_affiliation_strings":["2Fractal Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fractal Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210118680"]}]},{"author_position":"last","author":{"id":null,"display_name":"Jacques Dumas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151614","display_name":"Tetraphase Pharmaceuticals (United States)","ror":"https://ror.org/048830f73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacques Dumas","raw_affiliation_strings":["1Tetraphase Pharmaceuticals, Watertown, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Tetraphase Pharmaceuticals, Watertown, MA;","institution_ids":["https://openalex.org/I4210151614"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"3880","last_page":"3880"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.3312999904155731,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.3312999904155731,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.2305999994277954,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.09380000084638596,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tetracycline","display_name":"tetracycline","score":0.7879999876022339},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9829999804496765},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.8040000200271606},{"id":"https://openalex.org/keywords/leukemia-xenograft","display_name":"leukemia xenograft","score":0.7450000047683716},{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.6499999761581421},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.8399999737739563},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.5619999766349792},{"id":"https://openalex.org/keywords/in-vivo-efficacy","display_name":"in vivo efficacy","score":0.5270000100135803},{"id":"https://openalex.org/keywords/dose-linearity","display_name":"dose linearity","score":0.46799999475479126},{"id":"https://openalex.org/keywords/species-comparison","display_name":"species comparison","score":0.4790000021457672},{"id":"https://openalex.org/keywords/rats","display_name":"rats","score":0.9940000176429749},{"id":"https://openalex.org/keywords/monkeys","display_name":"monkeys","score":0.9919999837875366},{"id":"https://openalex.org/keywords/dogs","display_name":"dogs","score":0.3630000054836273}],"concepts":[{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.873375654220581},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.7483948469161987},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.6890790462493896},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.657282829284668},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6270923614501953},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3946576714515686},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2749338746070862},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23009073734283447},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.10749050974845886}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-3880","doi":"https://doi.org/10.1158/1538-7445.am2019-3880","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-3880","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4230576262","https://openalex.org/W2956070430","https://openalex.org/W1972608119","https://openalex.org/W2604021625","https://openalex.org/W4282939400","https://openalex.org/W2243019099","https://openalex.org/W2081136957","https://openalex.org/W2491467159","https://openalex.org/W7098692838","https://openalex.org/W2088605318"],"abstract_inverted_index":{"Abstract":[0],"The":[1,105,214],"pharmacokinetics":[2],"(PK)":[3],"of":[4,36,198,206,218,225,254,282,306,335,376,455,485,495],"TP-2846":[5,25,54,96,135,175,191,207,219,239,293,327,409,416,456],"was":[6,55,97,136,188,192,201,208,220,294],"studied":[7],"in":[8,52,133,194,210,215,222,242,245,298,325,388,410,430,443,445],"mice,":[9,53],"rats,":[10],"and":[11,16,33,41,60,63,103,142,179,212,237,276,284,348,360,383,424,447],"monkeys":[12],"via":[13],"IP,":[14],"PO,":[15],"IV":[17,49,102,323],"administration.":[18],"In":[19,47,91,129,321,414,482],"a":[20,92,130,223,248,279,303,458,487],"mouse":[21,227,432],"PK":[22,50,66,94,107,131,147,370,419],"study":[23,51,132,324],"with":[24,247,302,332,379,440],"dosed":[26,56,98,137,193,209,260,312,355],"IP":[27,261,313],"at":[28,57,68,99,138,149,262,287,314,356],"10":[29],"mg/kg,":[30,62,264,316,362],"Cmax,":[31],"T1/2,":[32],"AUC0-inf":[34,85,124,168],"values":[35,334],"5340":[37],"ng/mL,":[38],"6.81":[39],"h,":[40],"5944":[42],"ng\u2022h/mL":[43],"were":[44,386],"observed,":[45],"respectively.":[46],"an":[48,322],"1,":[58,139,357],"3,":[59],"6":[61,143,361],"the":[64,369,374,389,396,404,411,451,496],"various":[65,106],"parameters":[67,108,148,371],"each":[69,110,150],"respective":[70,151],"dose":[71,152],"are:":[72,113,153],"Cmax":[73,114,154],"=":[74,80,86,115,120,125,155,162,169,257,338,342,346,351],"1142,":[75],"5881,":[76],"8518":[77],"ng/mL;":[78,118,160],"T1/2":[79,119,161],"6.15,":[81],"5.15,":[82],"6.92":[83],"h;":[84,123,167],"704,":[87],"2174,":[88],"4205":[89],"ng\u2022h/mL.":[90,128,174],"rat":[93],"study,":[95],"5":[100],"mg/kg":[101,144],"PO.":[104],"by":[109],"dosing":[111,291,381,384],"route":[112],"7180,":[116],"4.39":[117],"9.64,":[121],"9.41":[122],"9390,":[126],"21.0":[127],"monkeys,":[134],"2,":[140,358],"4,":[141,359],"IV.":[145],"Key":[146],"734,":[156],"1071,":[157],"1835,":[158],"2715":[159],"9.97,":[163],"12.5,":[164],"15.7,":[165],"22.4":[166],"4128,":[170],"8252,":[171],"19179,":[172],"30871":[173],"demonstrated":[176,240,328,425],"good":[177],"half-lives":[178],"exposures":[180],"across":[181,421],"all":[182],"three":[183],"species.":[184],"Low":[185],"oral":[186],"bioavailability":[187],"observed":[189],"when":[190,203,259,311,354],"rats.":[195],"Dose":[196],"linearity":[197],"plasma":[199],"exposure":[200],"shown":[202],"varying":[204,380],"levels":[205,382],"mice":[211],"monkeys.":[213],"vivo":[216,243,483],"efficacy":[217,244,331,375,406,429],"evaluated":[221],"number":[224],"leukemia":[226,433],"xenograft":[228,300,412,434],"models":[229,301],"including":[230],"MV4-11,":[231],"MOLT-4,":[232],"CCRF-CEM,":[233],"HL-60,":[234,326],"KG-1,":[235],"Kasumi-1,":[236],"K-562.":[238],"potent":[241],"MV4-11":[246],"Tumor":[249],"Growth":[250],"Inhibition":[251],"(TGI)":[252],"value":[253,281,305],"111.4%":[255],"(p":[256,308,337,341,345,350],"0.001)":[258,310],"12.5":[263],"QD,":[265],"4":[266],"days":[267,269],"on/6":[268],"off,":[270],"for":[271,318,364,408,499],"two":[272,319,365],"cycles,":[273],"while":[274],"cytarabine":[275],"tigecycline":[277],"had":[278],"TGI":[280,304,333],"23.5%":[283],"-49.2%,":[285],"respectively,":[286,353],"their":[288],"reported":[289],"optimal":[290],"regimens.":[292],"also":[295],"highly":[296],"efficacious":[297],"HL-60":[299,390],"109.1%":[307],"<":[309],"20":[315],"QDx3,":[317,363],"weeks.":[320,366],"dose-responding":[329],"antitumor":[330],"5.38%":[336],"1.000),":[339],"34.73%":[340],"0.643),":[343],"103.50%":[344],"0.015),":[347],"104.87%":[349],"0.013),":[352],"To":[367],"understand":[368],"that":[372,401],"drive":[373],"TP-2846,":[377],"studies":[378],"schedules":[385],"conducted":[387],"model.":[391,413],"Subsequent":[392],"PK/PD":[393],"modeling":[394],"using":[395],"resulting":[397],"data":[398,437],"sets":[399],"suggested":[400],"AUC":[402],"is":[403],"primary":[405],"driver":[407],"summary,":[415],"displayed":[417],"favorable":[418],"profiles":[420],"multiple":[422],"species":[423],"potent,":[426],"dose-responding,":[427],"AUC-driven":[428],"several":[431],"models.":[435],"These":[436],"sets,":[438],"combined":[439],"other":[441],"desirable":[442],"vitro,":[444],"vivo,":[446],"chemical-physical":[448],"properties,":[449],"support":[450],"continued":[452],"pre-clinical":[453],"development":[454],"as":[457],"new":[459],"antileukemia":[460,490],"agent.":[461],"Citation":[462],"Format:":[463],"Xiao-Yi":[464],"Xiao,":[465],"Cuixiang":[466],"Sun,":[467],"Jian":[468],"Zhou,":[469],"Noriaki":[470],"Tatsuta,":[471],"Joseph":[472],"Newman,":[473],"Douglas":[474],"White,":[475],"Barbara":[476],"Hibner,":[477],"Arijit":[478],"Chakravarty,":[479],"Jacques":[480],"Dumas.":[481],"activities":[484],"TP-2846:":[486],"novel":[488],"tetracycline":[489],"agent":[491],"[abstract].":[492],"In:":[493],"Proceedings":[494],"American":[497],"Association":[498],"Cancer":[500,514],"Research":[501],"Annual":[502],"Meeting":[503],"2019;":[504],"2019":[505],"Mar":[506],"29-Apr":[507],"3;":[508],"Atlanta,":[509],"GA.":[510],"Philadelphia":[511],"(PA):":[512],"AACR;":[513],"Res":[515],"2019;79(13":[516],"Suppl):Abstract":[517],"nr":[518],"3880.":[519]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-12T00:00:00"}